British diabetes expert Clifford Bailey offers his take on the CANVAS data

Dr Cyrus Desouza reviews GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors, offering advice on which patients may benefit from each class.

Join Drs Vega and Anawalt as they discuss hot topics from ENDO 2017, including a new drug class for hot flashes and management of subclinical hypothyroidism in older adults.

Do SGLT-2 inhibitors reduce the risk for major cardiovascular events? Dr Wysham discusses hot-off-the-press results of the CANVAS program at ADA 2017.

For patients, knowing whether their kidney function is compromised and telling their doctor about it goes a long way toward preventing medication errors and complications.

What comes after basal insulin? Join us for a discussion of basal-plus therapy and tips for adding rapid insulin and GLP-1 receptor agonists.

When is 'low' too low? This and other topics in hypoglycemia are discussed, including current ADA definitions, symptom variability, and hypoglycemia awareness and unawareness.

In Pennsylvania, thousands of lives have been saved in the fight against the opioid epidemic. Dr Rachel Levine explains.

Why are some teenagers at risk for mental illness? Dr Kristie Whitaker, a researcher on adolescent brain development, aims to find out.

Can exogenous use of the 'love hormone' be disruptive? It's possible, says biologist and oxytocin researcher Dr Sue Carter.